Abstract:The alpha-cyanoarylmethyl-3, 4-dihydropyrimidin-4(3H)-ones (S-CN-DABOs) were reported as a kind of reverse transcriptase inhibitors of human immunodeficiency virus type-1 (HIV-1) by our group in 2007. In this paper, we proposed to expand the S-CN-DABO scaffold to enrich the structure-activity relationship (SAR) of the phenyl ring that was predicted to be located in the W229 hydrophobic pocket. Thirty-nine S-CN-DABO derivatives were manufactured to explore the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase. These analogues displayed up to low nanomolar activity against wild-type (WT) HIV-1 and good activity against several clinically relevant resistant mutant viruses, especially rilpivirine-associated resistant mutant E138K strain. The inhibitory ability toward the RT enzyme was significantly improved. Compound B23 with a 2, 6-difluoro-phenyl group showed inhibitory effects with an EC50 value of 20.8 nM against HIV-1 WT strain, and an EC50 of 50 nM targeting mutant E138K, which were about 20-fold better than the lead compound B1. Molecular docking analysis elucidated the biological activity and offered a structural insight for follow-up research. In addition, compound B23 also showed favorable drug-like properties in vitro and in vivo. There was no significant inhibition of hERG (IC50 > 40 mu M), no apparent CYP enzymatic inhibitory activity and acute toxicity in mouse models. Perfect oral bioavailability of compound B23 was revealed (F = 164%, SD rats). In summary, these S-CN-DABOs compounds could be further optimized and modified for promising drug candidates in anti-HIV clinical therapy.

5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.

5‐Alkyl‐2‐[(aryl and alkyloxycarbonylmethyl)thio]‐6‐(1‐naphthylmethyl) Pyrimidin‐4(3H)‐ones as an Unique HIV Reverse Transcriptase Inhibitors of S‐DABO Series.

Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or Α-Cyanoarylmethyl)-3,4-dihydropyrimidin-4(3h)-ones As Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.

Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodo-6-benzyl S-DABOs As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Non‐nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti‐HIV Activity of Novel 2‐[(arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3h)-ones As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

Towards New C6-rigid S-DABO HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Biological Investigation and Molecular Modeling Studies

Expansion of the S-CN-DABO Scaffold to Exploit the Impact on Inhibitory Activities Against the Non-Nucleoside HIV-1 Reverse Transcriptase.

Development of novel S -N 3 -DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Dihydro-alkoxyl-benzyl-oxopyrimidine Derivatives (dabos) As Non-Nucleoside Reverse Transcriptase Inhibitors: an Update Review (2001-2011).

Non‐nucleoside HIV Reverse Transcriptase Inhibitors. Part 6. Synthesis and Anti‐HIV Activity of Novel 2‐[(arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues.

Development of Novel S-N3-DABO Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Potency and Selectivity

Synthesis and Anti-Hiv Activity Evaluation of 1-[(Alkenyl or Alkynyl or Alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from <i>N</i>-Alkylation to Methyl Hopping on the Pyrimidine Ring